Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been granted an extension to its existing UK approval, for 12- to 17-year-olds. This extension has been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).
The approval follows a review of the safety, quality and effectiveness of the vaccine in this age group, and expert advice from the government's independent scientific advisory body, the Commission on Human Medicines.
No comments:
Post a Comment